{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Cirrhosis%2C+Biliary&page=2",
    "query": {
      "condition": "Liver Cirrhosis, Biliary",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Liver+Cirrhosis%2C+Biliary&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T12:28:44.830Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06060665",
      "title": "Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Biliary Cholangitis"
      ],
      "interventions": [
        {
          "name": "Seladelpar 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 96,
      "start_date": "2023-09-05",
      "completion_date": "2026-05-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 43,
      "location_summary": "Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06060665"
    },
    {
      "nct_id": "NCT03265249",
      "title": "BRIDGE Device for Post-operative Pain Control",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Liver Failure",
        "Liver Diseases, Alcoholic",
        "Liver Diseases",
        "Pain, Postoperative",
        "Transplant; Failure, Liver",
        "Liver Cirrhosis, Biliary"
      ],
      "interventions": [
        {
          "name": "BRIDGE device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 27,
      "start_date": "2018-02-12",
      "completion_date": "2020-04-03",
      "has_results": true,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03265249"
    },
    {
      "nct_id": "NCT02135536",
      "title": "Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cirrhosis"
      ],
      "interventions": [
        {
          "name": "NGM282",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2014-05",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2017-03-28",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Coronado, California • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02135536"
    },
    {
      "nct_id": "NCT02308111",
      "title": "Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Liver Cirrhosis, Biliary"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid (OCA)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 334,
      "start_date": "2014-12-26",
      "completion_date": "2021-12-23",
      "has_results": true,
      "last_update_posted_date": "2023-03-09",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 43,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Rialto, California + 32 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rialto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02308111"
    },
    {
      "nct_id": "NCT04526665",
      "title": "Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Biliary Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Elafibranor 80mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 161,
      "start_date": "2020-09-24",
      "completion_date": "2028-12-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 46,
      "location_summary": "Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04526665"
    },
    {
      "nct_id": "NCT01865812",
      "title": "Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Obeticholic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intercept Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2013-12-03",
      "completion_date": "2016-09-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Sacramento, California • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01865812"
    },
    {
      "nct_id": "NCT04385147",
      "title": "Advanced Endoscopy During COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cholangitis, Secondary Biliary",
        "Cholangiocarcinoma",
        "Obstructive Jaundice",
        "Pancreas Cancer",
        "COVID-19",
        "SARS-CoV-2"
      ],
      "interventions": [
        {
          "name": "Endoscopic management according to standard of care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Al-Azhar University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 670,
      "start_date": "2020-05-18",
      "completion_date": "2020-07-05",
      "has_results": false,
      "last_update_posted_date": "2020-07-08",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 1,
      "location_summary": "Albertson, New York",
      "locations": [
        {
          "city": "Albertson",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04385147"
    },
    {
      "nct_id": "NCT03124108",
      "title": "Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Biliary Cholangitis (PBC)"
      ],
      "interventions": [
        {
          "name": "Elafibranor 80 mg",
          "type": "DRUG"
        },
        {
          "name": "Elafibranor 120 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genfit",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 45,
      "start_date": "2017-04-05",
      "completion_date": "2018-10-31",
      "has_results": true,
      "last_update_posted_date": "2019-09-24",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03124108"
    },
    {
      "nct_id": "NCT01476995",
      "title": "Prognostic Indicators as Provided by the EPIC ClearView",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease",
        "Congestive Heart Failure",
        "Valvular Heart Disease",
        "Atrial Fibrillation",
        "Hypertension",
        "Pyelonephritis",
        "Acute Renal Failure",
        "Renal Failure",
        "Viral Hepatitis",
        "Alcoholic Hepatitis",
        "Steatohepatitis",
        "Cirrhosis",
        "Asthma",
        "COPD",
        "Bronchitis",
        "Emphysema",
        "Pneumonia",
        "Inflammatory Bowel Disease",
        "Crohn's Disease",
        "Ulcerative Colitis",
        "Diverticulitis",
        "Peptic Ulcer Disease",
        "Irritable Bowel Syndrome",
        "Cholecystitis",
        "Pancreatitis",
        "Malabsorption Disorders",
        "Celiac Sprue",
        "Diabetes"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Epic Research & Diagnostics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 353,
      "start_date": "2010-09",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2011-11-22",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01476995"
    },
    {
      "nct_id": "NCT04620733",
      "title": "RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Biliary Cholangitis"
      ],
      "interventions": [
        {
          "name": "Seladelpar 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Seladelpar 5 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 193,
      "start_date": "2021-04-21",
      "completion_date": "2023-08-11",
      "has_results": true,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-06-11T12:28:44.830Z",
      "location_count": 40,
      "location_summary": "Chandler, Arizona • Little Rock, Arkansas • Palo Alto, California + 31 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04620733"
    }
  ]
}